Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AFF2 intronic transcript 1 (AFF2-IT1) is a poorly characterized transcript, presumably arising from the intronic regions of the AFF2 gene. The canonical AFF2 gene encodes a nuclear protein involved in transcriptional regulation and alternative splicing[3][5]. Alterations in AFF2, such as expansions or intragenic duplications, are associated with X-linked intellectual disability (Fragile XE syndrome) and occasionally resemble Cornelia de Lange syndrome phenotypes[2][5]. There is no evidence that any intronic transcript, nor specifically AFF2-IT1, has recognized roles as a therapeutic target, biomarker, or drug-interacting molecule. The dominant clinical and biological relevance in the literature relates to the protein-coding gene (AFF2/FMR2), not to its intronic transcripts[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on AFF2 intronic transcript 1 (AFF2-IT1).